[Table_StockInfo] 买入 2024年 05月 07日 （首次） 证券研究报告•2024年一季报点评 当前价： 26.92元 光威复材（300699） 国防军工 目标价： 33.30元（6个月） 一季度业绩相对稳健，股权激励计划调整激发内生动力 投资要点 西南证券研究发展中心 [T ab事le件_S：u公mm司a发ry布] 2024年一季报，报告期内共实现营业收入5.1亿元，同比下降 [分Ta析bl师e_：Au刘th倩or倩] 8.1%，归属于上市公司股东的净利润1.6亿元，同比下降8.2%。 执业证号：S1250522070003  拓展纤维板块表现相对稳定，新增量迎来业绩新动能。2024Q1拓展纤维板块实 电话：15001276860 邮箱：lqqyf@swsc.com.cn 现营业收入3.2亿元，同比-7.1%。收入小幅下降主要原因为通用高性能碳纤维 价格下降；高强高模碳纤维产品需求节奏放缓。 [相Tab对le指_Q数u表ot现eP ic] 航空碳纤维方面，Q1航空定型产品大合同执行率8.6%，我们计算履行金额1.8 光威复材 沪深300 亿（含税），目前仍有1.8亿合同待执行，面临新 ...

Investment Rating - The report does not specify a clear investment rating for the company [1] Core Views - The company reported a revenue of 11.41 billion yuan in 2023, representing a year-on-year increase of 23.5%, and a net profit of 1.97 billion yuan, up 19.2% [2] - The first quarter of 2024 showed a revenue of 2.35 billion yuan, an increase of 6.2%, and a net profit of 360 million yuan, up 10.2% [2] - The growth in revenue is driven by both domestic and international markets, with domestic revenue at 9.5 billion yuan (+19.7%) and overseas revenue at 1.7 billion yuan (+54.0%) [2] - The company has expanded its business network to cover 65 countries and regions globally, with over 700 product registrations and certifications [2] - The release of restrictions on high-end medical equipment procurement is expected to accelerate demand for mid-to-high-end imaging equipment [2] Summary by Sections Financial Performance - In 2023, the revenue from medical imaging equipment was 9.93 billion yuan (+21.1%), maintenance service revenue was 1.07 billion yuan (+42.8%), and software revenue was 170 million yuan (+124.8%) [2] - The company expects revenues for 2024, 2025, and 2026 to be 13.9 billion yuan, 17.2 billion yuan, and 21.5 billion yuan respectively, with net profits of 2.4 billion yuan, 2.9 billion yuan, and 3.6 billion yuan [3][10] Business Segments - The revenue from imaging equipment is projected to grow at rates of 21% in 2024, 22% in 2025, and 24% in 2026, with a gross margin of approximately 47.8% [9] - Maintenance and technical service revenue is expected to grow at a compound annual growth rate (CAGR) of 30% from 2024 to 2026, with gross margins increasing to 65% by 2026 [9] - Software revenue is anticipated to grow at a CAGR of 50% during the same period, with a gross margin of 40% [9] Market Expansion - The company has achieved significant growth in overseas markets, with overseas revenue accounting for 14.7% of total revenue in 2023, an increase of 3 percentage points from 2022 [2] - The company has received multiple certifications, including CE and FDA approvals, enhancing its competitive position in both developed and emerging markets [2] Future Outlook - The company is expected to maintain a strong growth trajectory, with projected revenue growth rates of 22.25% in 2024, 23.42% in 2025, and 24.68% in 2026 [4] - The net profit growth rates are forecasted to be 20.92% in 2024, 22.77% in 2025, and 24.24% in 2026 [4]

Investment Rating - The report maintains a "Hold" rating for the company, indicating that the stock is expected to perform in line with the market over the next six months [11][16]. Core Insights - The company achieved a revenue of 889 million yuan in 2023, representing a year-on-year growth of 66.1%. The net profit attributable to the parent company was -90 million yuan. In Q1 2024, the company reported a revenue of 180 million yuan, up 32.6% year-on-year, with a net profit of 6.99 million yuan, an increase of 46.8% [16]. - The company is focusing on overseas markets and satellite internet, with significant growth in overseas revenue, which reached 320 million yuan in 2023, a 117.3% increase year-on-year. The company has also secured multiple domestic and international satellite internet core network projects [16][17]. - The gross margin improved to 40.5% in 2023, up 1.4 percentage points year-on-year, due to enhanced product value and effective cost control, with a comprehensive expense ratio of 43.9%, down 23.5 percentage points [16]. - The company is investing in quantum encryption, AI, and integrated scheduling technologies, with R&D expenditure of 200 million yuan in 2023, accounting for 22.8% of total revenue [16]. Financial Forecasts - The company is expected to achieve earnings per share (EPS) of 0.53 yuan, 0.83 yuan, and 1.06 yuan for the years 2024, 2025, and 2026, respectively, with corresponding price-to-earnings (PE) ratios of 35, 22, and 18 [16][17]. - Revenue projections for 2024 to 2026 are 884 million yuan, 1.293 billion yuan, and 1.896 billion yuan, with growth rates of 66.1%, 46.2%, and 46.6% respectively [17].

硅片盈利阶段性承压，行业底部逆势扩张 行业低谷保持正现金流入、逆势扩产锚定行业前三。2023 年、2024Q1 公司经 营活动产生的现金流量净额分别为 13.30、2.33 亿元。虽然 2024Q1 硅片行业 几乎全行业亏损，但公司仍保持正现金流入，行业低谷期体现较强抗风险能力。 2023 年上半年，公司单晶硅二期产能完成爬坡，同时目前公司单晶硅三期产能 已进入产能爬坡阶段，预计全部产能达产后公司产能将进入行业前三位。 盈利预测与投资建议。2024Q1硅片几乎全行业亏损，公司盈利阶段性承压同时， 保持正现金流入。公司在行业底部逆势扩张产能，若后续硅片行情回暖，公司 业绩弹性较大。预计公司 2024~2026年归母净利润分别为 10.21、13.94、19.33 亿元，对应 PE 分别为 12、9、6倍。参考同行业可比公司，给予 24年 14倍估 值，目标价 7.70 元，维持"买入"评级。 | --- | --- | --- | --- | --- | |----------------------------------|----------|----------|----------|---------- ...

Investment Rating - The report does not specify a clear investment rating for the company, but it suggests maintaining attention to the stock based on future performance expectations [2]. Core Views - The company reported a total revenue of 10.06 billion yuan in 2023, a year-on-year increase of 15.7%, and a net profit attributable to shareholders of 2.80 billion yuan, up 13.2% year-on-year [2]. - In Q1 2024, the company achieved a revenue of 3.171 billion yuan, representing a growth of 20.58%, and a net profit of 975 million yuan, an increase of 26.61% [2]. - The company plans to distribute a cash dividend of 23.2 yuan per 10 shares, totaling 1.4 billion yuan, which accounts for 50% of the net profit attributable to shareholders in 2023 [2]. Summary by Sections Revenue and Profitability - The pharmaceutical manufacturing segment generated revenue of 4.802 billion yuan in 2023, a growth of 25.94%, driven by significant sales increases in liver disease and cardiovascular drugs [2]. - The revenue from the pharmaceutical circulation segment was 4.205 billion yuan, a 3.6% increase, attributed to expanded sales channels and marketing efforts [2]. - The cosmetics business achieved revenue of 707 million yuan, up 11.42%, with notable sales from the Queen brand Pearl Cream exceeding 100 million yuan [2]. Cost and Margin Analysis - The gross margin for pharmaceutical manufacturing decreased by 2.93 percentage points due to rising costs of raw materials, particularly natural cow bile and other traditional Chinese medicine ingredients [2]. - The company’s R&D expenses were 232 million yuan in 2023, a 1.01% increase, with a focus on secondary development of its key products [2]. Future Earnings Forecast - The forecast for net profit attributable to shareholders for 2024-2026 is 3.38 billion yuan, 3.84 billion yuan, and 4.39 billion yuan, respectively, with corresponding P/E ratios of 43, 38, and 33 [2][3]. - The company expects to maintain a revenue growth rate of approximately 15% for its pharmaceutical manufacturing segment and 12% for its cosmetics business over the next few years [8]. Market Performance - The stock price has fluctuated between 188.51 yuan and 314.44 yuan over the past 52 weeks, with a current price of 242.98 yuan [6]. - The total market capitalization of the company is approximately 146.59 billion yuan [6]. Financial Metrics - The company’s return on equity (ROE) for 2023 was 20.48%, with projections of 20.91% for 2024 [3]. - The earnings per share (EPS) are expected to grow from 4.64 yuan in 2024 to 7.28 yuan by 2026 [3].

[Table_StockInfo] 买入 2024年 05月 05日 （维持） 证券研究报告•2023年年报及2024年一季报点评 当前价： 26.63元 福 莱 特（601865） 电力设备 目标价： 32.40元（6个月） 24Q1 业绩超预期，行业底部凸显盈利韧性 投资要点 西南证券研究发展中心 [T ab事le件_S：u公m司ma2ry02] 3年实现营业收入215.24亿元，同比增长39.21%；实现归母净 利润 27.60亿元，同比增长30.00%。2024Q1实现营业收入57.26亿元，同比 [分Ta析bl师e_：Au韩th晨or ] 增长6.73%；实现归母净利润7.60亿元，同比增长48.57%。 执业证号：S1250520100002 电话：021-58351923  光伏玻璃销量大增，行业底部盈利凸显韧性。2023年光伏组件价格大幅下跌刺 激了下游组件装机需求大幅增长。受益于公司新增产能释放和光伏行业需求旺 邮箱：hch@swsc.com.cn 盛，公司光伏玻璃营收、销量再创新高。2023年公司光伏玻璃销量12.20亿平 分析师：敖颖晨 （折合2.0mm口径），同比增长49.52%。 ...

[Table_StockInfo] 2024 年 05 月 03 日 证券研究报告•2023 年年报点评 买入 （维持） 当前价：14.55 元 天马科技（603668）农林牧渔 目标价：19.80 元（6 个月） 收入韧性强，利润受极端天气及周期波动有所下滑。2023 年公司业绩变化主要 系①饲料行业持续承压，饲料原料价格大幅波动、下游养殖业亏损，饲料企业运 营成本和资金周转压力加大；②特种水产养殖业务受 2023年一季度倒春寒和夏 季极端高温，以及近两年投苗量大而养殖基地建设尚未完全配套影响，目前养殖 密度整体偏高，客观上影响整体出鱼节奏；③宏观经济大环境等多重因素影响， 报告期内鳗鲡销售市场价格走势偏弱。 天马科技 沪深300 [Table_Report] 1. 天马科技（603668）：费用摊销影响利 润，鳗鱼业务弹性可期 (2023-11-08) 数据来源：Wind，西南证券 1）公司为特种水产饲料领导者，饲料业务预计稳定增长。预计 2024-2026 年畜禽饲料 销量增速分别为 10%、10%、5%；吨价增速分别为 0.4%、0%、0%。预计 2024-2026 年毛 利率分别为 8.5%、8.5 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 17.60 CNY over the next six months [1][11]. Core Insights - The company's Q1 2024 performance exceeded expectations, with a significant increase in revenue from 55nm products, indicating a recovery in market demand and improved operational efficiency [2][11]. - The company reported a total revenue of 7.24 billion CNY for 2023, a decrease of 27.9% year-on-year, but Q4 2023 showed a recovery with a revenue of 2.23 billion CNY, up 42.9% quarter-on-quarter [2][11]. - For Q1 2024, the company achieved a revenue of 2.23 billion CNY, representing a year-on-year growth of 104.4% [2][11]. Summary by Sections Financial Performance - The company’s revenue for 2023 was 7.24 billion CNY, with a net profit of 211.63 million CNY, down 93.1% year-on-year. The Q1 2024 revenue was 2.23 billion CNY, with a net profit of 80 million CNY, up 124% year-on-year [2][3][11]. - The gross margin for 2023 was 21.6%, while Q1 2024 saw an increase to 25.0% [2][11]. - The company’s cash flow from operating activities improved significantly in Q1 2024, with a net cash flow of 400 million CNY, up 197.2% year-on-year [2][11]. Product and Market Development - The product structure has been optimized, with the revenue share of 55nm products increasing significantly. In 2023, 55nm products accounted for 7.9% of total revenue, which further increased to 10.2% in Q1 2024 [2][11]. - The company is actively expanding its market presence in the OLED driver chip sector and has made progress in developing 40nm and 28nm technologies [2][11]. Earnings Forecast - The company is expected to achieve net profits of 880 million CNY, 1.38 billion CNY, and 1.58 billion CNY for 2024, 2025, and 2026, respectively, with corresponding growth rates of 317.8%, 55.6%, and 14.8% [3][11]. - The projected revenue for 2024 is 10.10 billion CNY, reflecting a growth rate of 39.4% [3][11]. Valuation - The report assigns a PE ratio of 40 for 2024, leading to a target price of 17.60 CNY, based on the company's strong market position and growth potential in the display driver IC sector [11][12].

[Table_StockInfo] 买入 2024年 05月 05日 （首次） 证券研究报告•23年年报&24Q1季报点评 当前价： 7.03元 徐工机械（000425） 机械设备 目标价： 9.18元（6个月） 海外业务稳定增长，盈利能力提升 投资要点 西南证券研究发展中心 [T a事ble件_：S公um司m发a布ry]2 023年年报和2024Q1业绩，23年实现营收928.5亿，同比-1.0%； 归母净利润53.3亿，同比+23.5%。24Q1公司实现营收241.7亿，同比+1.2%， [分Ta析bl师e_：Au邰th桂or龙] 归母净利润16.0亿，同比+5.1%。海外业务稳定增长，盈利能力提升。 执业证号：S1250521050002  国内工程机械下滑周期影响，起重机械、土方机械板块承压下滑；高机、矿机 电话：021-58351893 等新业务实现高增长。细分产品来看，23 年，传统板块部分业务受国内工程机 邮箱：tgl@swsc.com.cn 械行业下行周期影响，起重机械板块实现营收211.9亿，同比-11.2%，毛利率提 升至 22.6%，业务占比为22.8%；土方机械板块营收225.6亿 ...

Investment Rating - The investment rating for the company is "Buy" with a target price of 5.89 CNY over the next six months [1][3]. Core Insights - The company reported a steady increase in performance, with 2023 revenue reaching 26.5 billion CNY, a year-on-year growth of 11.2%. The net profit attributable to shareholders was 7.18 billion CNY, up 0.9% [2][3]. - The company continues to expand its installed capacity, with a total of 40.0 GW as of the end of 2023, and ongoing projects amounting to 18.8 GW [2][3]. - The company is a leader in the renewable energy sector, with significant growth in wind and solar power generation, and an increasing proportion of market-based electricity transactions [2][3]. Summary by Sections Financial Performance - In 2023, the company achieved operating revenue of 26.5 billion CNY, with a net profit of 7.18 billion CNY. The first quarter of 2024 saw revenue of 7.9 billion CNY, reflecting a 15.3% increase year-on-year [2][4]. - The wind power segment generated 18.6 billion CNY in revenue, a 10% increase, while the solar power segment brought in 7.41 billion CNY, growing by 13.4% [2][4]. Installed Capacity and Growth - The company added 13.54 GW of new installed capacity in 2023, with wind power contributing 3.49 GW and solar power 9.54 GW. The total installed capacity reached 40.0 GW, with wind power accounting for 19.4 GW [2][3]. - The company’s market share in the wind power sector is 4.4%, and in offshore wind, it is 14.7%. The solar power segment holds a 3.3% market share [2][3]. Profit Forecast and Valuation - The forecast for net profit attributable to shareholders for 2024-2026 is 8.94 billion CNY, 10.16 billion CNY, and 11.13 billion CNY, respectively, with corresponding EPS of 0.31, 0.36, and 0.39 CNY [3][4]. - The company is expected to maintain a high growth rate in installed capacity, with a CAGR of 36.9% from 2020 to 2023. A PE ratio of 19 times is applied for the 2024 valuation, leading to a target price of 5.89 CNY [3][4].